RhumbLine Advisers’s ICU Medical ICUI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.86M Buy
68,639
+490
+0.7% +$70.4K 0.01% 1119
2025
Q4
$9.72M Sell
68,149
-1,042
-2% -$140K 0.01% 1072
2025
Q3
$8.3M Buy
69,191
+210
+0.3% +$26.6K 0.01% 1169
2025
Q2
$9.12M Buy
68,981
+4,159
+6% +$564K 0.01% 1092
2025
Q1
$9M Sell
64,822
-3,069
-5% -$476K 0.01% 1063
2024
Q4
$10.5M Sell
67,891
-3,287
-5% -$556K 0.01% 1030
2024
Q3
$13M Buy
71,178
+4,262
+6% +$631K 0.01% 942
2024
Q2
$7.95M Buy
66,916
+12,519
+23% +$1.32M 0.01% 1141
2024
Q1
$5.84M Sell
54,397
-7,711
-12% -$767K 0.01% 1330
2023
Q4
$6.19M Sell
62,108
-154
-0.2% -$15.1K 0.01% 1285
2023
Q3
$7.41M Sell
62,262
-483
-0.8% -$72.1K 0.01% 1135
2023
Q2
$11.2M Sell
62,745
-2,270
-3% -$416K 0.01% 961
2023
Q1
$10.7M Sell
65,015
-433
-0.7% -$74.5K 0.01% 932
2022
Q4
$10.3M Buy
65,448
+4,507
+7% +$686K 0.01% 926
2022
Q3
$9.18M Buy
60,941
+1,829
+3% +$304K 0.01% 929
2022
Q2
$9.72M Buy
59,112
+5,957
+11% +$1.15M 0.01% 909
2022
Q1
$11.8M Sell
53,155
-1,352
-2% -$303K 0.02% 868
2021
Q4
$12.9M Buy
54,507
+1,192
+2% +$278K 0.02% 848
2021
Q3
$12.4M Sell
53,315
-1,451
-3% -$304K 0.02% 842
2021
Q2
$11.3M Sell
54,766
-739
-1% -$152K 0.01% 928
2021
Q1
$11.4M Sell
55,505
-548
-1% -$116K 0.02% 908
2020
Q4
$12M Buy
56,053
+154
+0.3% +$29.9K 0.02% 816
2020
Q3
$10.2M Sell
55,899
-1,331
-2% -$251K 0.02% 767
2020
Q2
$10.5M Buy
57,230
+1,616
+3% +$321K 0.02% 750
2020
Q1
$11.2M Buy
55,614
+2,832
+5% +$545K 0.02% 616
2019
Q4
$9.88M Sell
52,782
-548
-1% -$94.3K 0.02% 840
2019
Q3
$8.51M Buy
53,330
+3,771
+8% +$751K 0.02% 861
2019
Q2
$12.5M Buy
49,559
+3,658
+8% +$848K 0.02% 669
2019
Q1
$11M Buy
45,901
+575
+1% +$138K 0.02% 714
2018
Q4
$10.4M Buy
45,326
+12,261
+37% +$3.02M 0.02% 693
2018
Q3
$9.35M Buy
33,065
+164
+0.5% +$48K 0.02% 714
2018
Q2
$9.66M Buy
32,901
+1,692
+5% +$462K 0.02% 698
2018
Q1
$7.88M Sell
31,209
-4,959
-14% -$1.17M 0.02% 773
2017
Q4
$7.81M Buy
36,168
+5,037
+16% +$1.02M 0.02% 816
2017
Q3
$5.79M Buy
31,131
+575
+2% +$100K 0.01% 953
2017
Q2
$5.27M Sell
30,556
-243
-0.8% -$39K 0.01% 973
2017
Q1
$4.7M Buy
30,799
+8,790
+40% +$1.28M 0.01% 1042
2016
Q4
$3.24M Buy
22,009
+936
+4% +$135K 0.01% 1165
2016
Q3
$2.66M Buy
21,073
+1,119
+6% +$135K 0.01% 1228
2016
Q2
$2.25M Sell
19,954
-1,055
-5% -$109K 0.01% 1267
2016
Q1
$2.19M Buy
21,009
+1,425
+7% +$136K 0.01% 1318
2015
Q4
$2.21M Buy
19,584
+892
+5% +$98.6K 0.01% 1291
2015
Q3
$2.05M Buy
18,692
+977
+6% +$105K 0.01% 1307
2015
Q2
$1.7M Sell
17,715
-3,200
-15% -$299K 0.01% 1524
2015
Q1
$1.95M Buy
20,915
+200
+1% +$17.5K 0.01% 1426
2014
Q4
$1.7M Buy
20,715
+1,025
+5% +$78.6K ﹤0.01% 1470
2014
Q3
$1.26M Sell
19,690
-720
-4% -$44.1K ﹤0.01% 1603
2014
Q2
$1.24M Buy
20,410
+4,380
+27% +$259K ﹤0.01% 1686
2014
Q1
$960K Sell
16,030
-685
-4% -$42.2K ﹤0.01% 1831
2013
Q4
$1.06M Sell
16,715
-350
-2% -$22.5K ﹤0.01% 1768
2013
Q3
$1.16M Buy
17,065
+6
+0% +$428 ﹤0.01% 1686
2013
Q2
$1.23M Buy
+17,059
New +$1.13M ﹤0.01% 1622

Other funds holding ICUI

RhumbLine Advisers's ICUI Position: Q1 2026 in Review

RhumbLine Advisers increased its ICU Medical (ICUI) stake by 0.72% in Q1 2026, buying an estimated $70.4K and bringing the position to 68,639 shares worth $8.86M. The position accounts for 0.01% of the portfolio, ranked #1119.

RhumbLine Advisers first reported a position in ICUI in Q2 2013 and has held it in 52 quarters since. The position peaked at $13M in Q3 2024. 275 funds tracked by Wall St. Rank hold ICUI as of Q1 2026.

  • RhumbLine Advisers held 68,639 shares of ICU Medical worth $8.86M as of Q1 2026.
  • RhumbLine Advisers bought 490 ICU Medical shares in Q1 2026, an estimated $70.4K.
  • ICU Medical made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1119 holding.
  • RhumbLine Advisers first reported a position in ICU Medical in Q2 2013 and has held it in 52 quarters since.
  • RhumbLine Advisers's ICU Medical position peaked at $13M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held ICU Medical as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.